Skip to main content

Table 2 Baseline demographic and disease characteristics of patients who achieved remission in the consecutive measurement

From: Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort

  Remission
DAS28-ESR (n = 1160) CDAI (n = 930) SDAI (n = 946)
RF+, % 82.9 83.8 83.8
RF, average, IU/ml, mean (SD) 71.4 (100.2) 88.7 (189.0) 86.6 (183.3)
ESR, mm/h, mean (SD) 12.2 (8.5) 17.8 (14.4) 17.4 (13.9)
CRP, mg/L, mean (SD) 1.7 (3.9) 2.5 (8.4) 1.8 (4.0)
Measurement interval, mo., mean (SD) 12.2 (6.5) 12.4 (6.3) 12.4 (6.3)
MTX usage, % 61.3 61.9 61.4
MTX, mg, mean (SD) 7.6 (3.0) 7.5 (2.8) 7.5 (2.9)
Prednisolone usage, % 12.5 9.9 9.1
Prednisolone, mg, mean (SD) 4.1 (7.8) 4.7 (10.1) 4.5 (10.0)
bDMARD or tsDMARD usage, % 44.3 43.1 43.7
TNFα-i, % 23.7 25.8 26.5
IL6-i, % 18.6 10.3 10.1
CTLA4-Ig, % 3.8 6.4 6.4
JAK-i, % 0.1 0.6 0.7
  1. IL6-i interleukin 6 inhibitor, JAK-i Janus kinase inhibitor, TNFα-i tumor necrosis factor inhibitor